Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Entozyme Pty Ltd. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This activity is distributed to 1 distinct examiner and 1 distinct art unit. DAVID J STEADMAN is the busiest examiner, responsible for the 1 pending office action. The prosecution is currently centralized, with all active matters residing with a single examiner in a single art unit. This allows the applicant to focus entirely on the preferences and prior rulings of DAVID J STEADMAN without the need to reconcile different examiner viewpoints.
Since there is only 1 pending office action, the progress of the Biotechnology & Pharmaceuticals portfolio at the USPTO is currently tied to the resolution of this specific case within its assigned art unit. Practitioners should analyze the specific technical standards of the 1 distinct art unit involved to ensure the claims are properly supported. The concentration of the workload with a single examiner means that the applicant can build a direct rapport and understanding of the examiner's concerns. This focused strategy is efficient for managing a small portfolio where the outcome of a single pending action has a significant impact on the company's overall patent position.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEADMAN, DAVID J | 1 | 57.7% | +29.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18257767 | TRANSGENIC ANIMALS AND PREPARATIONS THEREOF FOR BIOREMEDIATION | STEADMAN, DAVID J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18257767 | TRANSGENIC ANIMALS AND PREPARATIONS THEREOF FOR BIOREMEDIATION | STEADMAN, DAVID J | — |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18257767 | TRANSGENIC ANIMALS AND PREPARATIONS THEREOF FOR BIOREMEDIATION | STEADMAN, DAVID J | 1656 | §101§102§103§112 | Non-Final OA | — | Pending | Jun 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEntozyme Pty Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
David J Steadman has the most, with 1 of Entozyme Pty Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
